第一上海(00227.HK)擬3192.5萬港元出售影像、內窺鏡檢查及體檢中心資產
格隆匯5月12日丨第一上海(00227.HK)公吿,於2022年5月12日,賣方國際醫療中心(香港)有限公司(公司全資附屬公司)與買方富惠發展有限公司訂立協議,據此,賣方同意按代價出售出售資產。
出售資產,即由賣方運營及位於香港德輔道中22號華懋中心一期1樓、2樓、3樓及5樓的影像、內窺鏡檢查及體檢中心的資產。根據協議,買賣出售資產的代價合共為港幣3192.5萬元。
出售事項將構成縮減規模過程的一部分,且董事認為,出售事項將使集團資源此後可更有效地分配至集團其他有利可圖的業務分部並由其使用,彼等相信這將對集團有利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.